Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 265

1.

Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.

Lonial S, Kaufman J, Reece D, Mateos MV, Laubach J, Richardson P.

Expert Opin Biol Ther. 2016 Aug 17:1-11. [Epub ahead of print]

PMID:
27533882
2.

Is Maintenance Therapy for Everyone?

Nooka AK, Lonial S.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S139-44. doi: 10.1016/j.clml.2016.02.011.

PMID:
27521311
3.

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, San Miguel J, Avet-Loiseau H.

Lancet Oncol. 2016 Aug;17(8):e328-46. doi: 10.1016/S1470-2045(16)30206-6. Review.

PMID:
27511158
4.

Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation.

Shah SP, Nooka AK, Jaye DL, Bahlis NJ, Lonial S, Boise LH.

Oncotarget. 2016 Jul 26. doi: 10.18632/oncotarget.10847. [Epub ahead of print]

5.

HLA polymorphism and risk of multiple myeloma.

Beksac M, Gragert L, Fingerson S, Maiers M, Zhang MJ, Albrecht M, Zhong X, Cozen W, Dispenzieri A, Lonial S, Hari P.

Leukemia. 2016 Jul 27. doi: 10.1038/leu.2016.199. [Epub ahead of print]

PMID:
27461064
6.

Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participation.

Nooka AK, Behera M, Lonial S, Dixon MD, Ramalingam SS, Pentz RD.

Cancer. 2016 Jul 12. doi: 10.1002/cncr.30090. [Epub ahead of print]

PMID:
27404488
7.

Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?

DeFilipp Z, Langston AA, Chen Z, Zhang C, Arellano ML, El Rassi F, Flowers CR, Kota VK, Al-Kadhimi Z, Veldman R, Jillella AP, Lonial S, Waller EK, Khoury HJ.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):466-471.e1. doi: 10.1016/j.clml.2016.04.017. Epub 2016 May 5.

PMID:
27297665
8.

Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin.

Elf S, Lin R, Xia S, Pan Y, Shan C, Wu S, Lonial S, Gaddh M, Arellano ML, Khoury HJ, Khuri FR, Lee BH, Boggon TJ, Fan J, Chen J.

Oncogene. 2016 Jun 6. doi: 10.1038/onc.2016.196. [Epub ahead of print]

PMID:
27270429
9.

New Targets and New Agents in High-Risk Multiple Myeloma.

Nooka AK, Lonial S.

Am Soc Clin Oncol Educ Book. 2016;35:e431-41. doi: 10.14694/EDBK_159516.

10.

Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.

Ponder KG, Matulis SM, Hitosugi S, Gupta VA, Sharp C, Burrows F, Nooka AK, Kaufman JL, Lonial S, Boise LH.

Cancer Biol Ther. 2016 Jul 2;17(7):769-77. doi: 10.1080/15384047.2016.1192086.

PMID:
27246906
11.

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser AK, Axel A, Feng H, Uhlar CM, Wang J, Khan I, Ahmadi T, Nahi H.

Blood. 2016 Jul 7;128(1):37-44. doi: 10.1182/blood-2016-03-705210. Epub 2016 May 23.

12.

Death by a thousand cuts: the slow demise of chemotherapy.

Nooka AK, Lonial S.

Cancer. 2016 Jul 1;122(13):1971-3. doi: 10.1002/cncr.30024. Epub 2016 May 18. No abstract available.

PMID:
27191541
13.

Novel Combination Treatments in Multiple Myeloma.

Nooka AK, Lonial S.

Oncology (Williston Park). 2016 May;30(5):451-65. Review.

14.

Lack of health maintenance examinations and risk in myeloma patients.

Tariman JD, Gleason C, Faiman B, Doss D, Catamero D, Bishop-Royse J, Katz M, Kurtin S, Moran D; IMF Nurse Leadership Board, Lonial S.

Cancer Med. 2016 Jul;5(7):1425-35. doi: 10.1002/cam4.716. Epub 2016 Apr 27.

15.

Myeloma Is Not a Single Disease.

Lonial S, Nooka AK.

J Oncol Pract. 2016 Apr;12(4):287-92. doi: 10.1200/JOP.2016.010926.

16.

Monoclonal antibodies in multiple myeloma: data from the 2015 ASH meeting.

Lonial S.

Clin Adv Hematol Oncol. 2016 Feb;14(2):82-4. No abstract available.

PMID:
27057804
17.

BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth.

Deng J, Park D, Wang M, Nooka A, Deng Q, Matulis S, Kaufman J, Lonial S, Boise LH, Galipeau J, Deng X.

Oncotarget. 2016 May 10;7(19):27753-63. doi: 10.18632/oncotarget.8513.

18.

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.

Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, Caers J, Hillengass J, San Miguel J, van de Donk NW, Einsele H, Bladé J, Durie BG, Goldschmidt H, Mateos MV, Palumbo A, Orlowski R.

Blood. 2016 Jun 16;127(24):2955-62. doi: 10.1182/blood-2016-01-631200. Epub 2016 Mar 21.

19.

Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.

Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Dias AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MC, Atilla E, Beksac M, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani SZ, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ.

Am J Hematol. 2016 Jun;91(6):575-80. doi: 10.1002/ajh.24351. Epub 2016 Apr 24.

PMID:
26955792
20.

Emerging treatments in Castleman disease - a critical appraisal of siltuximab.

Koff JL, Lonial S.

Biologics. 2016 Jan 25;10:9-15. doi: 10.2147/BTT.S60523. eCollection 2016. Review.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk